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Key Messages
1.  Since the launch of the cervical 
screening programme, the ever-
screened rate has increased 
significantly from 37% in 2003 
to 64% in 2008.
2. Using Hong Kong specific 
data on age-specific human 
papillomavirus (HPV) 
prevalence and cervical cancer 
incidence, the first cost-
effectiveness analysis of the 
role of adjunctive HPV DNA 
testing was conducted.
3. Based on the principle that 
revision to current practice 
should not reduce effectiveness, 
the cost-effectiveness analysis 
suggests that 1,1,3-yearly 
cytology screening with HPV 
DNA testing is an optimal 
testing paradigm.
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Introduction
In March 2004, the Department of Health (DH) launched Hong Kong’s first 
organised population-based cytologic (conventional or liquid-based) screening 
recall programme for women aged between 25 and 64 years. Women are 
recommended to undergo screening every 3 years following 2 consecutive 
annual negative cytologic smear results (“1,1,3-yearly smear cycle”).1 However, 
there has not been any formal evaluation of DH’s cervical screening programme, 
and there is a need to investigate whether and by what factors this programme 
would result in higher screening coverage.
 Given that persistent infection with high-risk human papillomavirus (HPV) 
subtypes is a necessary precursor to cervical carcinogenesis, the Hong Kong 
College of Obstetricians and Gynaecologists (HKCOG) suggested using HPV 
DNA testing as an adjunct to routine cytology screening.2 Before widely adopting 
this strategy, its cost-effectiveness needs to be carefully evaluated using local-
specific data.
 This study aimed to (1) assess intermediate outcomes of the DH’s cervical 
screening programme in terms of overall population coverage, stratified by 
socioeconomic determinants (ie equity of access), using a pre-post survey 
design; (2) predict the medium-to-long-term clinical effectiveness conferred by 
such population coverage patterns by fitting empirical parameters from objective 
1 into a previously developed age-period-cohort projection model;3 and (3) adapt 
and extend our previous state-transition Markov cost-effectiveness model4 to 
include HPV DNA testing as an adjunct to conventional or liquid-based cytology.
Methods
This study was conducted from June 2007 to July 2009. 
Objective 1
We used a pre-post survey design to assess the population coverage of cervical 
cytologic screening. We used the 2003 Population Health Survey5 (coded PHS-
2003) to extract data on the baseline coverage pattern before the launch of the 
cervical screening programme in 2004. To assess the current coverage, we 
designed a similar survey (coded SHS-2008) and conducted telephone interviews 
by random-digit dialling of all fixed, land-based telephone lines and sampling all 
women aged at least 25 years in the household.
 We compared SHS-2008 with PHS-2003 to assess the impact of the cervical 
screening programme. We used multivariate logistic regression to generate 
adjusted odds ratios (ORs) for potential personal characteristics that were 
associated with the tendency of cervical cancer screening. 
Objective 2
We adapted a previously developed maximum likelihood age-period-cohort 
(APC) model3 to project the likely avertable disease burden associated 
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with the level and pattern of screening uptake after the 
implementation of the cervical screening programme as 
assessed in objective 1.
 Data on cervical cancer incidence and mortality from 
January 1972 to December 2006 were based on the Hong 
Kong Cancer Registry. Statistics on population figures 
were obtained from the Census and Statistics Department. 
Incidence data were grouped from 1972-76 to 2002-06 into 
5-year periods and 5-year age-groups from 25-29 to 80-
84 years to give synthetic birth cohorts centred at 5-year 
intervals since 1892. Age-groups of <25 and >85 years 
were omitted due to small numbers.
 We fitted the data by Poisson regression to compute 
15-year projections of incidence rates to the period 2017-
21.3 We applied linear extrapolation of the seven observed 
periods and the seven most recent birth cohorts based on 
data from 1972 to 2006. This set of projected rates would 
reflect a continuation of the status quo of opportunistic 
screening in Hong Kong through 2021 (base case).
 Population mortality rates were combined with 
incidence rates to derive age-period-specific mortality to 
incidence (M/I) ratios using observed data from 1972-76 to 
2002-06. Assuming no change in cancer-specific survival 
over the projected time horizon, we applied a constant 
set of age-period-specific M/I ratios that were based on 
the two most recent observed periods and were smoothed 
using moving averages. To assess the impact of the new 
organised screening programme, we computed the number 
of cancer cases under different screening frequencies by 
applying the risk reduction estimates as per the International 
Agency for Research on Cancer (IARC). We derived these 
figures by calibrating the original IARC estimates, which 
were based on the comparator scenario of no screening, 
to Hong Kong’s status quo of opportunistic screening.3 
Projected incident case numbers obtained from the APC 
modelling were adjusted downwards based on these cancer 
incidence reduction figures, beginning from the period 
2007-11, assuming that all Hong Kong women would 
derive a similar level of benefit from screening compared 
with populations in the IARC study and irrespective of age 
and other characteristics. We assumed that the full benefit 
of the organised screening programme would only begin 
from 2007. The numbers of cancer-related deaths were then 
scaled pro rata according to the procedure using age-period-
specific M/I ratios as specified above.
Objective 3
To conduct the cost-effectiveness analysis for cervical 
screening strategies and the inclusion of HPV DNA testing as 
a triage, we developed an individual-based stochastic model, 
which simulated the natural history of cervical cancer. Each 
stochastic realisation of this model corresponded to the life 
history of an individual. A simulated individual entered 
the model at the age of 10 years without HPV infection. 
Once infected, the individual was free of lesions (HPV-
infected) for some time and then either cleared the infection 
or progresses to cervical intraepithelial neoplasia (CIN) 1. 
After CIN 1 was established, the individual may regress to 
earlier stages (normal or HPV-infected) or progress to CIN 
2,3. Similarly, with CIN 2,3, the individual may regress 
to earlier stages or progress to cervical cancer if the HPV 
causing the infection belonged to the high-risk group. Our 
assumptions regarding management of abnormal screening 
results were based on the Guidelines on Management of 
Abnormal Cervical Cytology published by HKCOG.2
 To perform the cost-effectiveness analysis using the 
natural history model, we needed to estimate the age-
specific probabilities of infection. We used two Hong Kong 
specific data sources for this procedure: (1) age-specific 
HPV prevalence data from a Hong Kong study conducted 
in 2002,6 and (2) age-specific cancer incidence data from 
the Hong Kong Cancer Registry.7
 We used the incremental cost-effectiveness ratio 
(ICER), defined as the marginal cost divided by the 
marginal health benefit compared with the next most 
effective non-dominated strategy, to evaluate the cost-
effectiveness of different strategies. Strategies with ICER 
below a predetermined threshold (an ICER threshold) were 
considered to be cost-effective. In this study, we interpreted 
the cost-effectiveness of strategies in the context of the 
World Health Organization (WHO) threshold of three times 
the gross domestic product (GDP), which was equivalent 
to around US$90 000 (the Hong Kong GDP was around 
US$29 820 to 30 781 in 2007 to 2009).8 We defined the 
optimal strategy as the strategy that yields the best health 
outcome among all cost-effective strategies.
 
Results 
Objective 1 
The telephone survey was conducted from December 2007 
to March 2008. We contacted 1858 women and successfully 
interviewed 1023, which corresponded to a response rate of 
55%. All comparisons were examined on weighted whole 
population samples, using age-specific weighting adjusted 
for the size of the land-based non-institutional population 
(excluding foreign domestic helpers). To assess the change 
in screening coverage since the launch of the DH’s cervical 
screening programme, we compared the results of SHS-
2008 to that of PHS-2003.5
 In SHS-2008, 64% of the respondents reported to 
have had cytology smears in the absence of symptoms (ie 
preventive screening), which was substantially higher than 
the 37% in PHS-2003 (Table 1). In particular, the ever-
screened rate increased sharply from 13% to 40% among 
those aged ≥65 years, and from 26% to 53% among those 
who did not have regular physical check-up.
 Among those who had been screened without symptoms, 
64% of the SHS-2008 respondents reported to have regular 
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screening, which was similar to that in PHS-2003 (60%). 
There was a significant decrease in regular-screening 
rate among those divorced/widowed (61% vs 37%) and 
significant increases among those economically active 
(Table 1).
 Our multivariate regression analysis suggested that 
respondents in SHS-2008 were more likely to have had 
preventive screening (OR, 4.3). Women were more likely 
to have had preventive screening if they had a secondary 
education or above (OR, 1.4-1.6) or a monthly income of 
≥HK$20 000 (OR, 1.8). In contrast, women were less likely 
to have had preventive screening if they were currently 
non-married (OR, 0.27) or aged ≥65 years (OR, 0.25). 
Among those who had ever had preventive screening, 
those who had regular physical check-up were more likely 
to have regular screening (OR, 6.8), whereas those who 
aged 45 to 64 years (OR, 0.7) or ≥65 years (OR, 0.1) were 
less likely to have regular screening than those aged 25 to 
44 years.
Objective 2
The maximum likelihood APC model predicted that there 
will be 5911 cervical cancer cases and 1428 deaths over the 
15 years from 2007 to 2016 under the base-case scenario 
of opportunistic screening (Fig 1). From the APC model, 
15-year projections from 2007 to 2021 estimated that if all 
women were screened every 1, 3, and 5 years, compared with 
the status quo of opportunistic screening, the incremental 
cumulative number of cases prevented (years of life saved) 
would be 5254 (32 000), 4655 (28 200) and 2322 (14 100), 
representing 89%, 79%, and 39% reductions, respectively 
(Fig 1).
Objective 3
We performed a cost-effectiveness analysis to compare 
different combinations of cytology screening and HPV 
DNA testing from annually to 5-yearly. We assumed that 
cytology testing had a sensitivity of 70% and 80% for CIN 1 
and CIN 2,3, respectively, and a specificity of 95%.9 We also 
assumed that HPV DNA test had a sensitivity of 83% and 
a specificity of 93%.10 We considered quality-adjusted life-
year (QALY) and cancer incidence reduction as outcome 
measures of screening strategies. We also calculated the 
total cost including both the treatment cost for CIN 2,3 and 
cervical cancer and the cost for cytology and HPV DNA 
tests (Table 2). Both the QALYs and costs were discounted 
at an annual rate of 3%.
 Table 3 shows the total cost, cancer incidence, cancer 
incidence reduction, QALY and ICER for different 
combination of strategies comprising cytology and HPV 
DNA tests. When there was no screening, the individual cost 
and QALY were US$66 and 28.80812 years, respectively. 
In the baseline scenario (60% screening coverage), all 
strategies averted around 50 to 60% cancer cases and saved 
8.94 to 10.52×10-3 QALYs (Table 3).
 We performed a pair-wise comparison of screening 
strategies with and without HPV DNA testing (Table 3). The 
addition of HPV DNA testing to cytology-only strategies 
resulted in more QALYs at the expense of a higher costs 
and would be cost-effective for regular screening every 
≥3 years under the WHO ICER threshold (US$90 000 per 
QALY). When considering all screening strategies, all the 
cytology-only screening strategies were dominated (Fig 
2). The optimal screening strategy was regular, 4-yearly 
cytology screening with HPV DNA testing.
Table 1. Comparison of screening practice between PHS-2003 
and SHS-2008
Variable % of women 
who had been 
screened 
preventively
% of women 
who have regular 
screening among 
those who had 
been screened 
preventively
PHS-
2003
SHS-
2008
PHS-
2003
SHS-
2008
Overall 37 64 60 64
Age-group (years)
25-44 41 65 63 73
45-64 44 74 58 61
≥65 13 40 36 28
Marital status
Single 18 25 53 61
Married 45 80 60 68
Divorced/widowed 27 51 61 37
Monthly income (HK$)
1-9999 38 61 57 64
10 000-19 999 40 53 63 74
≥20 000 54 68 58 78
No income 34 67 60 58
Occupation
Professionals 42 58 54 79
White-collar 40 63 61 70
Blue-collar 39 61 54 71
Economically inactive 34 67 60 58
Physical check-up
Yes 65 79 79 78
No 26 53 43 41
Table 2. Treatment and test costs in cost-effectiveness 
analysis
Parameter* Cost (US$)
Treatment
CIN 2,311 733
Local ICC11 13 172
Regional ICC11 14 098
Distant ICC11 22 580
Test
Administration11 30
Cytology smear11 10
Human papillomavirus DNA12 49
Colposcopy and biopsy11 284
Health status Utility13
No cancer 1
CIN 1 0.91
CIN 2,3 0.87
Local ICC 0.76
Regional ICC 0.67
Distant ICC 0.48
Cancer survivor 0.84
* CIN denotes cervical intraepithelial neoplasia, ICC invasive cervical cancer
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Strategy Cost (US$)
No. of cervical cancer 
cases per 100 000 
women (reduction %*)
Quality-adjusted 
life-year saved 
(10-3 year)*
Incremental cost-
effectiveness 
ratio†
Incremental cost-
effectiveness ratio‡
No screening 66 1506 - - -
Cytology, 5-yearly 200 787 (48) 8.94 - 14 979
Cytology+HPV, 5-yearly 215 741 (51) 9.43 32 505 32 505
Cytology, 4-yearly 223 749 (50) 9.41 - Dominated
Cytology+HPV, 4-yearly 241 707 (53) 9.75 52 139 78 902
Cytology, 3-yearly 262 708 (53) 9.83 - Dominated
Cytology+HPV, 3-yearly 283 672 (55) 10.08 83 601 127 516
Cytology, 2-yearly 333 675 (55) 10.17 - Dominated
Cytology+HPV, 2-yearly 360 646 (57) 10.31 191 352 345 363
Cytology, 1-yearly 532 645 (57) 10.44 - Dominated
Cytology+HPV, 1-yearly 573 626 (58) 10.52 532 132 678 118
Table 3. Cost-effectiveness analysis comparing different cytology screening and human papillomavirus (HPV) DNA testing 
strategies up to age 65 years
* Calculated using ‘no screening’ as the reference
† Comparing cytology screening and HPV DNA testing strategies versus cytology screening only strategies at the same interval
‡ Comparing the next most-effective non-dominated strategy
Fig 1. Cumulative incident cases and deaths from cervical cancer (1972 to 2021) under different screening scenarios
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Fig 2. Cost-effectiveness of different combinations of cytology screening and human papillomavirus (HPV) DNA testing. 
Strategies without an underline are dominated.
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Discussion 
Objective 1
The ever-screened rate in the absence of symptoms (ie 
preventive screening) increased from 37% in PHS2003 
to 64% in SHS-2008 and an increase was uniformly 
observed when subjects were stratified by socioeconomic 
determinants. These results suggest that cervical screening 
programme has increased coverage in the general population 
and has been particularly successful in boosting the ever-
screened rate among those with very low baseline tendency 
to do so (ie those aged ≥65 years and those with no regular 
physical check-up). However, the ever-screened rate among 
those aged ≥65 years remained low at 40%. The programme 
recommends that women aged ≥65 years undergo screening 
if they have never been screened before or if the most recent 
screening was performed a long time ago.1, 2 The low ever-
screened rate among women aged ≥65 years may be due to 
their misconception that women who are sexually inactive 
or postmenopausal do not benefit from it.1 Overall, while 
the ever-screened rate has significantly increased since the 
launch of the programme, the current rate of 64% should be 
further increased to maximise the benefits.
Objective 2
In terms of policy implementation, the screening programme 
launched in Hong Kong in 2004 was really a government-
operated programme, which provided a prospective record 
and recall function for those who had ever been screened.1 
The programme encouraged women to undergo regular 
cytologic examination through social marketing campaigns 
for the general public, via primary care and women’s 
health providers on an opportunistic basis. For women who 
decided to get screened, they could be tested at public or 
private care providers on a full fee-for-service basis and 
these providers were then encouraged to enter the screened 
woman’s details into a centralised database for subsequent 
automatic recall (every 3 years) and archiving of test results. 
For an ideal programme, it is important to explicitly anchor 
the screening to proactive and personalised invitations 
(initial ‘call’ function).
Objective 3
Although HPV DNA testing could be used as an adjunct to 
cervical cancer screening,2 its role has not been addressed 
by the cervical screening programme.1 Using Hong Kong 
specific data on age-specific HPV prevalence and cervical 
cancer incidence, we provided the first cost-effectiveness 
analysis on this topic. Under the WHO ICER threshold 
(defined as three times the local GDP, which is US$90 000), 
our cost-effectiveness analysis suggested that adding HPV 
DNA testing to cytology-only screening would be cost-
effective if the regular screening interval was ≥3 years (Table 
3). Therefore, our analysis supports adding HPV DNA testing 
to the current recommended 1,1,3-yearly screening strategy. 
Our analysis suggests that among all screening strategies, 
screening with cytology and HPV DNA testing every 4 years 
is the optimal strategy. However, although the 1,1,4-yearly 
cytology with HPV DNA testing strategy was more cost-
effective than 3-yearly cytology screening alone, the former 
was less effective in preventing cervical cancer. Based on 
the principle that revision to current practice should not 
reduce effectiveness, our analysis suggests that 1,1,3-yearly 
cytology screening with HPV DNA testing is optimal.
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